Serum 25-hydroxyvitamin D level is negatively associated with serum phosphorus level among stage 3a-5 chronic kidney disease patients

Nokeety, Mahmoud M El; Heikal, Ahmed A.; Marzouk, Khaled; Hammad, Hany; Abdulazim, Dina O.; Salem, Mona M; Din, Usama A Sharaf El

doi:10.1016/j.nefroe.2018.02.015

Cited by 2 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, serum 25 (OH) vit D is the most reliable index of vitamin D status in normal and CKD patients [5, 6]. Elevated serum uric acid (SUA) and serum phosphorus are frequently encountered in CKD patients [7-9]. Previous studies have reported negative associations of serum 25 (OH) vit D with either SUA or serum phosphorus [9, 10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Urate Lowering Therapy Using Allopurinol Improves Serum 25 Hydroxy Vitamin D in Stage 3-5 CKD Patients: A Pilot Study

Mohammed

Marie

Abdulazim

et al. 2020

Nephron

Self Cite

View full text Add to dashboard Cite

Background: Recent studies have demonstrated negative associations of serum uric acid (SUA) with serum 25 hydroxy vitamin D (25 [OH] vit D) among CKD patients. Objective: The aim of the study was to look for the impact of hypouricemic therapy using allopurinol on serum level of 25 (OH) vit D in CKD patients. Cases and Methods: Seventy-two CKD stage 3–5 patients were selected to this study. Patients with SUA above 7 mg/dL were allocated to hypouricemic therapy using allopurinol (group I). A control group of cases not suffering marked increase in SUA were included as control group (group II). All cases were followed up for 3 months. Serum Cr, SUA, ionized calcium (SiCa), phosphorus, 25 (OH) vitD, parathyroid hormone (PTH), and 24-h urine protein were estimated at entry and by the end of the study. Results: At least 20 cases completed the study in each group. Serum 25 (OH) vit D significantly increased in group I (26.4 [14.1] vs. 39.6 [14.8] at entry vs. at end of the study, p < 0.001). In addition, SUA, PTH, and urine protein significantly decreased (11 [1.6] vs. 3.95 [0.58] mg/dL, 267.5 [97.5] vs. 225.5 [153] ng/mL, and 2.7 [1.18] vs. 1.5 [1.08] gm/day, p < 0.001, = 0.043, and <0.001 respectively). SiCa and phosphorus significantly increased (4.4 [0.3] vs. 5.2 [0.5] mg/dL and 4.25 [0.72] vs. 4.9 [0.75] mg/dL, p < 0.001 and = 0.007, respectively). Conclusion: This study supports a negative causal relationship between SUA and serum 25 (OH) vit D. Further studies are still needed to confirm this conclusion.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Elevated serum uric acid (SUA) and serum phosphorus are frequently encountered in CKD patients [7-9]. Previous studies have reported negative associations of serum 25 (OH) vit D with either SUA or serum phosphorus [9, 10]. So far, there is no clear explanation for these negative associations.…”

Section: Introductionmentioning

confidence: 99%